Volume 37, Issue 3 pp. 302-307
Full Access

Herpes zoster in children with bone marrow transplantation: Report from a single institution

HIDEKI NAKAYAMA

Corresponding Author

HIDEKI NAKAYAMA

Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan

Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan

Department of Pediatrics, Faculty of Medicine, Kyushu University, Maidashi 3-1-1, Higashi-ku, Fukuoka 812, Japan.Search for more papers by this author
JUN OKAMURA

JUN OKAMURA

Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan

Search for more papers by this author
SHOUICHI OHGA

SHOUICHI OHGA

Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan

Search for more papers by this author
CHIAKI MIYAZAKI

CHIAKI MIYAZAKI

Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan

Search for more papers by this author
AKINOBU MATSUZAKI

AKINOBU MATSUZAKI

Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan

Search for more papers by this author
YOSHIKO IKUNO

YOSHIKO IKUNO

Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan

Search for more papers by this author
KOHJI UEDA

KOHJI UEDA

Department of Pediatrics, Faculty of Medicine, Kyushu University, Fukuoka, Japan

Search for more papers by this author
HIDEKO TASAKA

HIDEKO TASAKA

Section of Pediatrics, National Kyushu Cancer Center, Fukuoka, Japan

Search for more papers by this author
First published: June 1995
Citations: 13

Abstract

Herpes zoster (HZ) has been often observed after bone marrow transplantation (BMT) in childhood. The occurrence of HZ was reviewed in children who received BMT. The clinical features of HZ were reviewed in 44 children who underwent BMT at Kyushu Cancer Center. Among the 35 recipients with a history of varicella before BMT, several factors associated with BMT and the lymphocyte subsets were compared between the patients who developed HZ (HZ + group) and those who did not (HZ- group). Twenty-two recipients (50%) developed HZ; in two-thirds of these cases (15/22: 68%), HZ occurred between 80 and 120 days after BMT (median 101 days). The recipients treated with busulfan had a higher occurrence of HZ than those treated without it. The patients with Grade II-IV acute graft-versus-host disease (GVHD) developed HZ more frequently. In the HZ + group, the absolute number of lymphocytes, CD3+, CD4+ or CD8+ cells at 3 months was significantly lower than that observed at 12 months after BMT and the CD4/CD8 ratio was significantly lower at 1 month than after 3 months of BMT. In conclusion, recipients were susceptible to HZ at around 100 days after BMT. The development of HZ may be associated with unbalanced T lymphocytes at that time.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.